Global Onychomycosis Treatment Market - 2024-2031

Global Onychomycosis Treatment Market - 2024-2031

Global Onychomycosis Treatment Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031

Onychomycosis is an infection of the nail caused by fungi such as dermatophytes, non-dermatophyte moulds and yeasts (mainly Candida species) in which 80% of the toenail infections are caused by dermatophytes (Trichophyton rubrum). Onychomycosis is classified clinically as distal and lateral subungual onychomycosis (DLSO), superficial white onychomycosis (SWO), proximal subungual onychomycosis (PSO), candidial onychomycosis and total dystrophic onychomycosis.



Market Dynamics: Drivers & Restraints

Rise in the prevalence of diabetes

Onychomycosis is a common fungal infection affecting a significant portion of the population worldwide. As awareness of the condition grows and diagnostic techniques improve, more cases are diagnosed, leading to an increased demand for treatments.

For instance, onychomycosis is more common in diabetics than non-diabetics, and diabetics are at greater risk of serious complications from onychomycosis. According to the International Diabetes Federation 2021, around 537 million adults (20-79 years) are living with diabetes, 1 in 10. This number is expected to rise to reach 643 million by 2030 and 783 million by 2045. This in turn is expected to aid in the growth onychomycosis treatment market.

Furthermore, global onychomycosis treatments are also driven by various other factors like a rise in the advancements in treatment options, a rise in the prevalence of fungal infections and others helping the market to grow during the forecast period.

Lack of awareness

The market for onychomycosis is hindered by a lack of awareness about the condition, leading to undiagnosed nail fungal infections. People often ignore symptoms like decolourization, thickening of nails, and separation from the nail bed, preventing treatment. This lack of awareness and the potential side effects of onychomycosis treatment drugs also contribute to the market's potential for future decline. Therefore, it is predicted that the market will suffer in the assessment period.

For more details on this report – Request for Sample

Segment Analysis

The global onychomycosis treatment market is segmented based on type, treatment type, end-user and region.

The oral therapy from the treatment type segment accounted for approximately 41.3% of the onychomycosis treatment market share

The oral therapy from the treatment type segment accounted for approximately 41.3%. The most commonly used oral drugs for the treatment of onychomycosis are griseofulvin, terbinafine, itraconazole and ketoconazole. The disadvantages of oral antifungal agents are, they require a longer treatment period and they have more side effects, e.g. terbinafine (Lamisil). This drug is taken daily for 8 weeks for fingernail fungus and 12 weeks for toenail fungus. The most frequent side effects of Lamisil are headache, gastrointestinal disturbance (diarrhoea and/or dyspepsia), rash and elevated liver enzymes.

Geographical Analysis

North America is estimated to hold about 40.4% of the total market share throughout the forecast period

North America is estimated to hold about 40.4% of the total market share throughout the forecast period owing to factors like rising prevalence of onychomycosis in adults/elderly population and increasing awareness about safe and effective treatment in the region. Also, ongoing clinical trials, novel product launches and others help the region to have the highest market share during the forecast period.

For instance, in January 2024, Vanda Pharmaceuticals Inc. (Vanda) stated that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.

Covid 19 Impact Analysis

The covid 19 pandemic had a significant impact on the onychomycosis market where before the COVID-19 pandemic, clinical examinations, dermoscopy, and mycological examinations were recommended for patients with suspected onychomycosis. As the pandemic spreads, non-urgent in-patient visits are postponed, and telemedicine may be used for diagnosis and treatment.

Market Segmentation

By Type
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candida Onychomycosis
• Total Dystrophic Onychomycosis

By Treatment Type
• Oral therapy
• Topical Therapy
• Photodynamic Therapy
• CiclopiroxNail Lacquers
• Others

By End User
• Hospitals
• Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Bausch Health Companies Inc., Novartis AG, Pfizer, Inc., Moberg Pharma AB, Bayer AG, Dr Reddy’s Laboratories Ltd, Gladerma, Medimetriks Pharmaceuticals, Inc., Kaken Pharmaceuticals, Hahn Medical Systems among others.

Key Developments

 In February 2024, Moberg Pharma Abs marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals, launched sales of MOB-015 under the Terclara brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

 In July 2022, Zydus Lifesciences subsidiary received approval from the US health regulator to market an antifungal Efinaconazole Topical solution. Zydus Worldwide DMCC received final approval from the US Food and Drug Administration (USFDA) to market the product. Efinaconazole is an antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.

Why Purchase the Report??
• To visualize the global onychomycosis treatment market segmentation based on type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of the onychomycosis treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global onychomycosis treatment market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies